Key Highlights

  • Underlying operating profit rose 9.1% to A$260.9 million for the year to 30 June 2026.
  • Statutory net profit after tax fell 5.9% to A$186.9 million.
  • The sale of the travel insurance businesses, including World Nomads, is expected to complete in the first half of FY27 and deliver about A$97 million of net cash.
  • The full-year Dividend rose to 34.0 cents per share from 29.0 cents, with a target Payout Ratio of 65% to 75%.

The answer from its FY26 result, released on 24 August 2026 for the year to 30 June 2026, is that the health insurer is simplifying its portfolio and returning Capital while underlying Earnings grow. The company (ASX:NHF) operates in this market.

The central development: simplifying the group

The travel sale is the key structural change. According to the company, the sale of the nib Travel businesses is expected to complete in 1H27 and to deliver about A$97 million of net cash, of which about A$24 million funds a special dividend. The final dividend of 21.0 cents per share includes a 5 cent Special Dividend linked to the sale, and the full-year dividend is 34.0 cents, up from 29.0 cents. The target payout ratio rises to 65% to 75%. The final dividend has a Record Date of 4 September 2026 and was payable on 7 October 2026.

Why it matters: nib is refocusing on Health Insurance and related health services, which are more closely tied to its core capabilities. Removing travel also removes a cyclical, event-sensitive earnings source.

Business model and Revenue drivers

nib earns premiums from private health insurance, mainly for Australian residents, and from health cover for international students and workers, plus a New Zealand insurance operation, a health services arm and a National Disability Insurance Scheme (NDIS) plan-management business. Total income rose 6.2% to A$3,854.8 million. Profit depends on premium growth, claims costs, expense ratios and regulated mechanisms such as risk equalisation, which pools some claims costs across insurers.

FY26 segment results:

Australian residents health insurance: UOP fell 9.6% to A$187.9 million. Insurance revenue rose 6.4% to A$3.0 billion and net policyholder growth was 1.9%. Net Margin stayed inside the 6% to 7% target.

International health insurance: UOP rose 15.1% to A$35.1 million, with insurance revenue up 7.4% to A$236.9 million and policyholders up 4.4%.

New Zealand: UOP was A$27.5 million, against a A$2.9 million loss in FY25, reflecting pricing and claims recovery actions.

nib Health Services: UOP was A$2.4 million against a A$5.9 million loss, its first full year of profitability.

nib Thrive (NDIS): UOP was A$16.3 million, down 3.6%.

residents Business is by far the largest profit contributor, so its 9.6% decline matters. Growth elsewhere, particularly in New Zealand and international students, offset it at the group level.

Why profit rose underlying but fell statutorily

UOP excludes certain items, and the group's statutory NPAT fell 5.9%. Management described NPAT as "ahead of expectations", and it expects significantly lower one-off costs in FY27, which suggests that one-off items weighed on FY26.

Outlook and guidance

For FY27, nib guided to group UOP of A$265 million to A$285 million, excluding nib Travel and subject to risk equalisation. It is a company forecast, not a certainty.

Balance sheet and cash flow

Debt fell to A$204.8 million, gearing was 15.2% and Leverage was 0.6 times. These figures indicate a low-leverage Balance Sheet for a regulated insurer, which supports the higher payout target, although insurers must also hold regulatory capital, which limits how much cash can be distributed.

Sector and competitive position

Australian private health insurance is concentrated among a few large funds, with nib one of the larger listed players alongside Medibank. Competition centres on price, product design, Brand and service. Growth in international student cover and in New Zealand diversify nib away from Australian residents, but those segments are exposed to migration and policy settings. The company cited claims Inflation of 4.1% (4.5% including New South Wales bed rate changes), which pressures margins when premium increases are constrained.

Material risks

Risk equalisation: results and FY27 guidance depend on its outcome, and the company flagged volatility.

Rebate treatment: higher offer cost impacts followed the clarification of how Government Rebate is treated.

Claims inflation: 4.1% (4.5% with bed rate changes), which can outpace approved premium rises.

Regulation: premium approvals and other policy changes affect pricing.

Transaction risk: the travel sale has not yet completed, and the cash proceeds are an expectation.

International exposure: student and worker numbers depend on policy and demand.

Dependency on a large segment: Australian residents earnings fell in FY26.